Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: A case-control and a case-series study

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Yao, Song ^a   Sucheston, Lara E ^a   Millen, Amy E ^b   Johnson, Candace S ^a   Trump, Donald L ^a   Nesline, Mary K ^a   Davis, Warren ^a   Hong, Chi Chen ^a   McCann, Susan E ^a   Hwang, Helena ^a   Kulkarni, Swati ^a   Edge, Stephen B ^a   O'Connor, Tracey L ^a   Ambrosone, Christine B ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; 25-HYDROXYVITAMIN D; DRUG DERIVATIVE; VITAMIN D;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RISK; CASE CONTROL STUDY; CASE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; PREMENOPAUSE; PROGNOSIS; RISK REDUCTION; VITAMIN BLOOD LEVEL; BLOOD; BREAST TUMOR; CARCINOMA; COHORT ANALYSIS; MIDDLE AGED; OSMOLARITY; PHYSIOLOGY; POSTMENOPAUSE; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; OSMOLAR CONCENTRATION; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; RISK ASSESSMENT; VITAMIN D;

EID: 79952207467     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017251     Document Type: Article

References (41)

1. Deeb KK, Trump DL, Johnson CS, (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7: 684-700.
2. IARC (2008) Vitamin D and cancer. Lyon, France International Agency for Research on Cancer.
3. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, et al. (2010) Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer [Epub ahead of print].
4. Giovannucci E, (2010) Epidemiology of vitamin D and colorectal cancer: casual or causal link? J Steroid Biochem Mol Biol 121: 349-354.
5. Welsh J, (2004) Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 80: 1721S-1724S.
6. Welsh J, (2007) Vitamin D and prevention of breast cancer. Acta Pharmacol Sin 28: 1373-1382.
7. Bertone-Johnson ER, (2009) Vitamin D and breast cancer. Ann Epidemiol 19: 462-467.
8. Chen P, Hu P, Xie D, Qin Y, Wang F, et al. (2010) Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat 121: 469-477.
9. Yin L, Grandi N, Raum E, Haug U, Arndt V, et al. (2010) Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 46: 2196-2205.
10. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
11. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
12. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, et al. (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374.
13. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295: 2492-2502.
14. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, et al. (2010) Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med 7: e1000279.
15. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, et al. (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109: 123-139.
16. Ma H, Wang Y, Sullivan-Halley J, Weiss L, Marchbanks PA, et al. (2010) Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Cancer Res 70: 575-587.
17. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, et al. (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11: R31.
18. Li H, Stampfer MJ, Hollis JB, Mucci LA, Gaziano JM, et al. (2007) A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med 4: e103.
19. Rainville C, Khan Y, Tisman G, (2009) Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series. Cases J 2: 8390.
20. Ambrosone CB, Nesline MK, Davis W, (2006) Establishing a cancer center data bank and biorepository for multidisciplinary research. Cancer Epidemiol Biomarkers Prev 15: 1575-1577.
21. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, et al. (2007) Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7: 134.
22. Ahn J, Peters U, Albanes D, Purdue MP, Abnet CC, et al. (2008) Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst 100: 796-804.
23. Palmieri C, MacGregor T, Girgis S, Vigushin D, (2006) Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol 59: 1334-1336.
24. Neuhouser ML, Sorensen B, Hollis BW, Ambs A, Ulrich CM, et al. (2008) Vitamin D insufficiency in a multiethnic cohort of breast cancer survivors. Am J Clin Nutr 88: 133-139.
25. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N, (2009) Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27: 3757-3763.
26. Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, et al. (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 14: 1991-1997.
27. Abbas S, Chang-Claude J, Linseisen J, (2009) Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study. Int J Cancer 124: 250-255.
28. Abbas S, Linseisen J, Chang-Claude J, (2007) Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. Nutr Cancer 59: 54-61.
29. Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, et al. (2008) Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 29: 93-99.
30. Lin J, Manson JE, Lee IM, Cook NR, Buring JE, et al. (2007) Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 167: 1050-1059.
31. McCullough ML, Rodriguez C, Diver WR, Feigelson HS, Stevens VL, et al. (2005) Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 14: 2898-2904.
32. McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, et al. (2009) Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res 11: R64.
33. Kuper H, Yang L, Sandin S, Lof M, Adami HO, et al. (2009) Prospective study of solar exposure, dietary vitamin D intake, and risk of breast cancer among middle-aged women. Cancer Epidemiol Biomarkers Prev 18: 2558-2561.
34. Zinser GM, Suckow M, Welsh J, (2005) Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. J Steroid Biochem Mol Biol 97: 153-164.
35. Lopes N, Sousa B, Martins D, Gomes M, Vieira D, et al. (2010) Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions Vitamin D pathways unbalanced in breast lesions. BMC Cancer 10: 483.
36. Banwell CM, MacCartney DP, Guy M, Miles AE, Uskokovic MR, et al. (2006) Altered nuclear receptor corepressor expression attenuates vitamin D receptor signaling in breast cancer cells. Clin Cancer Res 12: 2004-2013.
37. Swami S, Krishnan AV, Feldman D, (2000) 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 6: 3371-3379.
38. Knight JA, Wong J, Blackmore KM, Raboud JM, Vieth R, (2010) Vitamin D association with estradiol and progesterone in young women. Cancer Causes Control 21: 479-483.
39. Artaza JN, Norris KC, (2009) Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchymal multipotent cells. J Endocrinol 200: 207-221.
40. Matthews D, LaPorta E, Zinser GM, Narvaez CJ, Welsh J, (2010) Genomic vitamin D signaling in breast cancer: Insights from animal models and human cells. J Steroid Biochem Mol Biol 121: 362-367.
41. Pendas-Franco N, Gonzalez-Sancho JM, Suarez Y, Aguilera O, Steinmeyer A, et al. (2007) Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 75: 193-207.